Lakefront Biotherapeutics NV (LKFT) News & Events

$28.880

-0.549 (-1.90%)At close

LKFT News

9.008-25NASDAQ.COM

Lakefront Biotherapeutics Receives FDA Orphan Drug Designation for Gamgertamig

9.008-24Newsfilter

Lakefront Biotherapeutics Receives FDA Orphan Drug Designation for Gamgertamig

6.508-24Newsfilter

Bank of America Acquires Over 10% Voting Rights in Lakefront Biotherapeutics

9.508-20PRnewswire

Keymed Biosciences Reports Strong Interim Results for H1 2026

9.508-20Newsfilter

Keymed Biosciences Reports Strong Interim Results for H1 2026

4.007-10seekingalpha

Morgan Stanley Resumes Coverage of Lakefront Biotherapeutics with Equal Weight Rating

8.006-09seekingalpha

Lakefront Biotherapeutics Announces €50M Share Repurchase Program

8.506-07Yahoo Finance

Gilead Acquires Ouro Medicines to Enhance Immunology Pipeline

8.506-04Newsfilter

Gilead and Lakefront Complete Acquisition of Ouro Medicines to Expand Inflammation Pipeline

Show More News

LKFT Events

8/24 16:30

Lakefront Biotherapeutic Receives FDA Orphan Drug Designation

Lakefront Biotherapeutic (LKFT) announced that the FDA has granted orphan drug designation to gamgertamig for the treatment of pemphigus. Gamgertamig was previously granted both Fast Track and Orphan Drug Designation by the FDA for the treatment of autoimmune hemolytic anemia and immune thrombocytopenia. Gamgertamig is being developed by Lakefront in collaboration with Gilead (GILD). Ongoing clinical trials in autoimmune diseases are actively enrolling, and expansion of the clinical trials program is anticipated in 2027.

Show More Events

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.